BAPETEN Ensures Safety Across Radioisotope Production And Use In Indonesia

Jakarta – The Indonesian Nuclear Energy Regulatory Agency (BAPETEN) is reinforcing a comprehensive safety culture that spans from the production of radioisotopes to their final application. This was evident just a day after a public seminar on Cesium-137, as BAPETEN convened a critical coordination meeting on Radiation Safety and Quality Control in the Production of Radioisotopes and Radiopharmaceuticals on December 18, 2025.

Chaired by Acting Head of BAPETEN Zainal Arifin, the hybrid meeting aimed to strengthen synergy, align perspectives, and boost the collective commitment of stakeholders, including the Ministry of Health, the National Research and Innovation Agency (BRIN), and producers. Arifin expressed his hope that the meeting would yield a more comprehensive understanding and actionable recommendations for safe, quality, and sustainable use of these materials in Indonesian healthcare.

This focus on the production phase is a foundational element of national safety. BAPETEN's regulations provide a detailed framework for production facilities, including the mandatory role of Radiation Protection Officers who are tasked with everything from routine safety monitoring to designing facilities and managing radiation accident emergencies. The recent meeting included presentations on strategic health sector plans, oversight challenges, and practical sharing sessions from national cancer centers and industry.

Read: Performance And Speed: Realme C85 5G Hits Indonesia With 144Hz Display And Dimensity Chip

The timing of these coordinated efforts highlights BAPETEN's dual-track strategy: engaging the public on the responsible use of technology[citation:] while simultaneously tightening the regulatory framework for the scientists, engineers, and corporations that produce and handle these substances. This ensures safety is ingrained at every step of the supply chain.

Zainal Arifin has consistently highlighted that compliance with safety and licensing regulations is non-negotiable for any entity utilizing radioisotopes like Cesium-137[citation:]. The agency's mandate is to provide legal certainty and enforce standards that protect workers, communities, and ecosystems from potential harm[citation:].

Participants in the production meeting included all hospitals with cyclotron facilities for producing radiopharmaceuticals, industrial license applicants, and related BAPETEN units. Discussions covered practical needs such as specialized training and certification in nuclear medicine, indicating a focus on building long-term human resource capacity.

By addressing both the beginning (production) and end (utilization) of the radioisotope lifecycle, BAPETEN is constructing a robust national safety regime. These efforts ensure that the diagnosis and treatment of thousands of patients relying on nuclear medicine, as well as various industrial applications, are supported by materials produced under the strictest safety protocols, safeguarding Indonesia's present and future.

---

BAPETEN Coordination Nuclear Safety Meeting Radiation Quality Control Radioisotope Production Safety Radiopharmaceutical Indonesia